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Abstract Deubiquitinating enzymes (DUBs) constitute a
diverse protein family and their impact on numerous bio-
logical and pathological processes has now been widely
appreciated. Many DUB functions have to be tightly con-
trolled within the cell, and this can be achieved in several
ways, such as substrate-induced conformational changes,
binding to adaptor proteins, proteolytic cleavage, and post-
translational modiﬁcations (PTMs). This review is focused
on the role of PTMs including monoubiquitination,
sumoylation, acetylation, and phosphorylation as charac-
terized and putative regulative factors of DUB function.
Although this aspect of DUB functionality has not been
yet thoroughly studied, PTMs represent a versatile and
reversible method of controlling the role of DUBs in bio-
logical processes. In several cases PTMs might constitute a
feedback mechanism insuring proper functioning of the
ubiquitin proteasome system and other DUB-related
pathways.
Keywords Ubiquitin  Protease  Post-translational
modiﬁcation  Phosphorylation  Acetylation 
Ubiquitination  Deubiquitination  Deubiquitinating
enzymes
Abbreviations
UCH Ubiquitin C-terminal hydrolase
USP Ubiquitin-speciﬁc protease
OTU Ovarian tumor domain
PTM Post-translational modiﬁcation
Introduction
The human genome encodes for approximately 80 putative
deubiquitinating enzymes (DUBs), including cysteine
proteases and several metalloproteases [1]. The diverse
functions that DUBs play within the cell can be classiﬁed
into three major categories. Firstly, DUBs process linear
polyubiquitin precursor proteins, such as ribosomal fusion
proteins, into single ubiquitin molecules (reviewed in [2]).
Secondly, DUBs recycle ubiquitin by processing poly-
ubiquitin chains to generate free ubiquitin that can subse-
quently enter the ubiquitin pool for subsequent ubiquitin
conjugation events. This is a critical process since free
polyubiquitin chains can inhibit the binding of polyubiq-
uitinated substrates to the 26S proteasome competitively
[3–5]. Finally, DUBs remove ubiquitin from ubiquitinated
substrates, antagonizing ubiquitin conjugation by E3 liga-
ses [6, 7]. The vast number of DUBs belonging to ﬁve
distinct protein families suggests that there is a special-
ization in terms of their function and speciﬁcity. Indeed, it
has been demonstrated that DUBs target distinct pathways
and their localization may be limited to certain subcellular
compartments [1, 8]. Moreover, many DUBs have been
linked to pathological conditions, underlying their physi-
ological signiﬁcance in health and disease (reviewed in
[9]).
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Since the catalytic activity of DUBs is so speciﬁc and in
many cases functionally critical, one would anticipate
multiple mechanisms of its control, and several ones have
been already described (reviewed in [10]). DUBs are
generally expressed as active enzymes, rather than inactive
precursors. However, certain DUBs require ubiquitin
binding to obtain their active conformation and that pre-
vents their uncontrolled proteolytic activity. The structural
data for several DUBs reveal that ubiquitin-binding by
DUBs is accompanied by active site rearrangements and
that such conformational alterations induce their hydro-
lytic activity, which has been demonstrated for OTUB1,
UCH-L1, UCH-L3, USP7, USP14, and S. cerevisiae
YUH1 [11–19]. Another way of modulating DUB activity
is through the binding of scaffold and adaptor proteins.
Some DUBs display low afﬁnity for ubiquitin and there-
fore require additional interactors for binding ubiquitinat-
ed substrates efﬁciently [20]. DUBs may require to be
incorporated into large macromolecular complexes to
attain the active state, exempliﬁed by USP14 or POH1 that
are activated by their binding to the 26S proteasome
complex [10, 21, 22]. Activation of USP8 and AMSH is
facilitated by signal transducing adaptor molecule 2
(STAM2), and both proteins are involved in regulating
endocytic trafﬁcking [23]. Protein–protein interactions can
also inhibit protease activity, for example UCH37 function
is inhibited by its binding to the chromatin-remodeling
complex [24]. Proteolytic cleavage of DUBs is another
way of regulation of their function. This is exempliﬁed by
USP1, which undergoes autoproteolysis that in turn inac-
tivates this enzyme [25]. Last but not least, many DUBs
are subjected to post-translational modiﬁcations (PTMs),
possibly representing an effective and reversible means of
regulating their activity or function. This review will
discuss the documented examples of the PTMs in DUBs
and their various phenotypic consequences (summarized in
Table 1).
Phosphorylation of CYLD in the NF-jB Pathway
The ubiquitin-speciﬁc protease involved in cylindromatosis
(CYLD) is one of the best studied examples of post-
translationally modiﬁed DUBs. CYLD speciﬁcally cleaves
Lys
63-linked polyubiquitin chains and acts on TRAF2,
TRAF6, and several other substrates, which results in
negative regulation of the NF-jB pathway ([26–28],
reviewed in [29]). CYLD is a tumor suppressor and an
important player in the host defense mechanisms against
bacterial infection, as shown for several pathogens [30–33].
CYLD becomes phosphorylated as a response to treatment
with a number of NF-jB-inducing factors, such as LPS or
TNF-a [34]. This transient modiﬁcation occurs at several
sites in a region located within close proximity to
the TRAF2-binding site, which includes Ser
418. The
biochemical analysis using phosphomimetic mutants
demonstrated that this PTM negatively affects the
deubiquitinating activity of CYLD on TRAF2, most likely
through interfering with the catalytic activity of CYLD,
since the binding of TRAF2 to a CYLD mutant mimicking
phosphorylation on Ser
418 is not affected (Fig. 1a; [34]).
There is some initial evidence that IKKc (I kappa B kinase
gamma) mediates CYLD phosphorylation on Ser
418 [34],
although a more recent report suggests that IKKe (I kappa
B kinase epsilon) is a much more efﬁcient kinase for this
site [35]. Interestingly, IKKa (I kappa B kinase alpha) and
IKKß (I kappa B kinase beta) are also able to phosphory-
late CYLD in vitro, although in vivo they require addi-
tional assistance of IKKc. In addition to down-regulation of
the NF-jB pathway [34], CYLD phosphorylation has been
demonstrated to have a physiological relevance in
increasing cell transformation [35], hence precise identiﬁ-
cation of a kinase or a kinase cascade involved in this
process might provide potential targets for pharmacologi-
cal intervention strategies in the treatment of cancer.
Phosphorylation-Regulated Activity of A20
A20 is an ovarian tumor domain (OTU)-containing prote-
ase with a well-deﬁned function in pro-inﬂammatory
events. It down-regulates activation of the transcription
factor NF-jB and therefore plays an important role in
inﬂammation [36–38]. Interestingly, next to the OTU
domain involved in cleavage of Lys
63-linked polyubiquitin
chains from the protein substrates TRAFs, RIPs and
NEMO, it also contains the C-terminal zinc ﬁnger domain
that acts as a ubiquitin ligase and is responsible for building
Lys
48-linked polyubiquitin conjugates on RIPs, thus tar-
geting them to the proteasome [39, 40]. Therefore, A20 has
a dual, or editing function on its substrates, removing
one type of polyubiquitin chain and attaching another. A
positional scanning peptide library technique combined
with a bioinformatics approach identiﬁed A20 as a putative
substrate for the IKKß kinase. Mass spectrometric analysis
mapped the phosphorylation site to Ser
381 that was veriﬁed
in vitro and in vivo. IKKß-mediated A20 phosphorylation
has been shown to increase its activity toward NEMO,
thereby further down-regulating the NF-jB pathway. It is
not conclusive, however, whether phosphorylation on
Ser
381 affects the E3 ubiquitin ligase or deubiquitinase
activity of A20, although the modiﬁcation occurs at the
zinc ﬁnger domain of the protein, so the former would be
expected [41].
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123Post-Translational Modiﬁcations Modulate Function
of Ataxin-3
Ataxin-3 (AT3) is a polyglutamine disease protein regu-
lating ERAD substrate trafﬁcking to the proteasome. It
contains an N-terminal Josephin domain [42] and prefer-
entially cleaves Lys
63-polyubiquitin chains, displaying
even higher activity toward Lys
63-ubiquitin linkages
that are within mixed linkage ubiquitin chains [43]. AT3
undergoes ubiquitination [44], which increases its ability
to process hexa-ubiquitin chains but in the tested condi-
tions it does not alter its speciﬁcity to the linkage type [45].
This observation has been made for both wild-type AT3
and the pathogenic AT3 with polyQ expansion causing a
neurodegenerative disorder, spinocerebellar ataxia type
3/Machado-Joseph disease (SCA3/MJD). Ubiquitination of
AT3 can be induced by certain stress factors, including
inhibition of the proteasome or treatment with dithiothre-
itol (DTT) that promotes the unfolded protein response
(UPR). It has therefore been proposed that AT3 is regulated
by a feedback loop mechanism that helps to restore the
homeostasis related to the ubiquitin pathway [45]. More-
over, AT3 is phosphorylated by protein casein kinase 2
(CK2). Phosphorylation occurs within the ubiquitin inter-
acting motif (UIM) of AT3 and is critical for the nuclear
localization of normal and pathogenic AT3. Inhibition of
AT3 phosphorylation contributes to its decreased translo-
cation to the nucleus and formation of nuclear inclusions.
CK2-dependent phosphorylation of AT3 might be crucial
in the stress response, because thermal stress has been
shown to increase the CK2-modulated nuclear abundance
of AT3. Furthermore, phosphorylation might also stabilize
AT3, as observed in a pulse-chase experiment using an
AT3 mutant mimicking phosphorylation [46].
Otubain 1 Phosphorylation Interferes with its Catalytic
Activity and Function in Bacterial Infection
Otubain 1 (OTUB1), a member of OTU-containing protein
family, is the only DUB for which speciﬁcity for Lys
48-
ubiquitin linkages has been clearly documented [12, 47].
OTUB1 functions in T cell anergy [48, 49], infection with
Yersinia [50] and in DNA double strand break repair [51].
OTUB1 is predicted to have multiple phosphorylation sites,




26 [50]. Phosphomimicry analysis suggests that
phosphorylation on these sites inﬂuences protein–protein
binding and the ability of OTUB1 to react with a ubiquitin-
based active-site probe, indicating reduction of its catalytic
activity. OTUB1-mediated stabilization of a small GTPase
RhoA involved in cytoskeletal alterations has been nega-
tively regulated by phosphorylation, which might be either
due to decreased protein–protein binding capabilities or a
lower catalytic activity. Finally, the physiological rele-
vance of this modiﬁcation is highlighted by the fact that
OTUB1 phosphomimetic mutants did not inﬂuence bacte-
rial invasion, in contrast to the wildtype OTUB1 [50]. The
phosphorylation sites are all located in the N-terminal part
of OTUB1, a domain that has been shown to be critical to
exert its function in regulating DNA double strand break
repair, indicating a possible regulatory mechanism [51, 52].
Ubp-M Phosphorylation on the Onset of Mitosis
A novel ubiquitin-processing protease Ubp-M (USP16) has
been recently identiﬁed in the pool of proteins phosphor-
ylated during mitosis [53]. Its function is yet unknown,
but it has been postulated that Ubp-M might interfere with
cell viability by modifying chromatin functions. The fact
that Ubp-M is capable of deubiquitinating histone H2A
in vitro is consistent with this hypothesis. Interestingly,
Fig. 1 PTMs in control of DUB activity exempliﬁed by CYLD and
UCH-L1. a Phosphorylation of CYLD impairs its deubiquitinating
activity toward TRAF2. CYLD cleaves Lys
63-linked polyubiquitin
chains from TRAF2, which results in negative regulation of the
NF-jB pathway by inactivation of kinases JNK and IKK. IKKc-
mediated phosphorylation impairs its catalytic activity, in effect
contributing to activation of JNK and IKK and positive regulation of
NF-jB. b Monoubiquitination of UCH-L1 modulates its enzymatic
function. UCH-L1 shortens conjugated polyubiquitin chains on the
substrate proteins, and monoubiquitination of UCH-L1 hinders this
activity by impairing its binding to ubiquitin. UCH-L1 is able to self-
regulate its own ubiquitination status through auto-deubiquitination
24 Cell Biochem Biophys (2011) 60:21–38
123phosphorylation does not interfere with the enzymatic
activity of this DUB, but it does correlate with histone H2A
deubiquitination during the cell cycle. Ubp-M gets rapidly
dephosphorylated during a shift from metaphase to ana-
phase [53, 54].
Post-Translational Modiﬁcations of UCH-L1 Involved
in Neurodegenerative Diseases
UCH-L1, a ubiquitin C-terminal hydrolase involved in
Parkinson’s disease and other neurodegenerative disorders
(reviewed in [55]), is highly expressed in neurons but its
substrates and function have not yet been deﬁned. UCH-L1
is O-glycosylated in the nerve terminals, although this
modiﬁcation has not been shown to have any effect on its
function [56]. Moreover, UCH-L1 undergoes monoubiq-
uitination at multiple lysines within close proximity to its
active site. This PTM appears to control the enzymatic
function of UCH-L1 since monoubiquitination impairs its
binding to ubiquitin and an ability to increase the mono-
ubiquitin pool in cells, but it has no effect on its localiza-
tion (Fig. 1b). Importantly, UCH-L1 is able to regulate its
own ubiquitination status through auto-deubiquitination,
therefore controlling its catalytic capabilities in an auto-
regulatory feedback loop [57].
Ubiquitination of USP6 in the Context of Protein–
Protein Interaction
USP6 (TRE17) is a ubiquitin-speciﬁc protease implicated
in human neoplasia with unidentiﬁed targets for its DUB
activity [58]. It has been shown to be mono- and poly-
ubiquitinated, and mono-ubiquitination of USP6 depends
on its association with calcium (Ca
2?)-binding protein
calmodulin (CaM). USP6 can promote its own deubiqui-
tination, suggesting a possible mode of auto-regulation, but
the physiological relevance of this modiﬁcation, including
the effect on its catalytic activity, remains to be uncovered
[59].
USP7—A Deubiquitinase Involved in Tumor
Development is Phosphorylated and Ubiquitinated
USP7 (Herpes-associated USP; HAUSP), a DUB described
predominantly for its role in cancer biology, is involved in
processes such as transcriptional regulation, DNA replica-
tion, apoptosis, and possibly in endosomal organization
([60], reviewed in [61, 62]). It interacts with p53, Hdm2
and Hdmx, and its deubiquitinating function towards these
proteins protects cells from apoptosis [63, 64]. PTMs
documented for USP7 include phosphorylation on Ser
18
and Ser
963, and ubiquitination on Lys
869, although any
relation of these modiﬁcations to its activity has not been
demonstrated so far [65, 66]. Ser
18 is likely to be a target
for casein kinase 2 (CK2)-mediated phosphorylation,
especially since CK2 co-immunoprecipitates with USP7,
suggesting their possible interaction [66]. Both phosphor-
ylation sites of USP7 are located near its protein–protein
interaction domains, similarly to the ones of CYLD [34]. It
is therefore plausible that this modiﬁcation might have an
effect on USP7 substrates or possibly other protein inter-
actions. Interestingly, the ubiquitination site of USP7 is
placed close to the region where it was reported to interact
with ICP0, a viral E3 ubiquitin ligase [67], supporting the
previous ﬁnding that ICP0 targets USP7 for ubiquitination
[68].
Role of Phosphorylation Events in the Activity
and Stability of USP8
USP8 (UBPY) plays a role in endosomal sorting by
deubiquitinating ligand-activated epidermal growth factor
(EGFR) on early endosomes [69]. A mass spectrometry-
based analysis of the phosphoproteome identiﬁed USP8 as
an interactor of 14-3-3e during anaphase, and two inde-
pendent studies mapped the phosphorylation site to Ser
680
[70, 71]. This site has been then demonstrated to be critical
for the subcellular localization of USP8, and while the
wildtype USP8 localizes primarily to the cytosol, the
majority of USP8 was found in the nucleus if the Ser
680
was mutated to alanine [70, 71], but this ﬁnding was not
supported by another study [72]. Furthermore, the catalytic
activity of USP8 is inhibited by phosphorylation on Ser
680,
based on the fact that the S680A mutant of USP8 exhibites
enhanced DUB activity toward polyubiquitin chains and
EGFR. This phosphorylation-mediated regulation of USP8
is present during the interphase, while during the M phase
USP8 is dephosphorylated [72]. Another study found USP8
to be a substrate for the EGF-activated Src-family tyrosine
kinases although its biological signiﬁcance is not yet
understood and the phosphorylation sites mediated by these
kinases have not been mapped thus far [73]. USP8 is also
phosphorylated by Akt on Thr
907, which contributes to its
stability [74, 75].
Translocation and Stabilization of USP10 is Mediated
by Phosphorylation
USP10 has been recently described as a DUB targeting p53
for polyubiquitin chain cleavage [76]. As mentioned ear-
lier, USP7 is a DUB that deubiquitinates p53 and its E3
Cell Biochem Biophys (2011) 60:21–38 25
123ligase Hdm2 [63], but in contrast to USP7, USP10 has been
only found to interact with and deubiquitinate p53, and it is
predominantly localized in the cytoplasm in unstressed
cells, while USP7 is mainly a nuclear protein [76].
Therefore, while USP7 targets p53 in the nucleus, USP10
deubiquitinates cytoplasmic p53 and upon genotoxic stress
it translocates to the nucleus to activate p53. ATM phos-
phorylates USP10 on Thr
42 and Ser
337, and this event is
required for the stabilization of USP10 and its translocation
into nucleus after DNA damage. The alanine mutation of
the Thr
42/Ser
337 has not been shown to interfere with the
capability of USP10 to deubiquitinate p53, but it impedes
its nucleolar translocation and stabilization, which in effect
suppresses USP10-mediated activation of p53 in response
to DNA damage [76].
Various PTMs of USP25 and their Effect on its
Catalytic Activity
The physiological role of USP25, a member of the USP
family [77] remains to be explored. This USP contains a
ubiquitin-associated domain (UBA) as well as two ubiq-
uitin binding-domains (UBDs, [78]), and its muscular
isoform interacts with three sarcomeric proteins, having a
stabilizing effect on one of them, myosin binding protein
C1 (MyBPC1; [79]). Recently, the tyrosine kinase SYK has
been found to phosphorylate USP25, predictably on the
Tyr
740 residue. The protease activity of USP25 is not
affected by SYK-mediated phosphorylation, but it decrea-
ses its protein levels, although not due to its increased
proteasomal degradation [80]. USP25 is also modiﬁed by
SUMO-1 and SUMO-2/3, among which the latter PTM has
been shown to be more predominant. Sumoylation occurs
on Lys
99 and Lys
141, which are located within the ubiqui-
tin-interacting motif (UIM), required for the protease
activity of USP25. USP25 sumoylation indeed inhibits the
catalytic activity of USP25 imposed by its reduced binding
to polyubiquitin chains [81]. Moreover, ubiquitination of
muscular isoforms of USP25 has also been detected, and
similarly to sumoylation it affected Lys
99. Mutation of this
residue negatively regulates USP25-mediated stabilization
of MyBPC1 and a mutually exclusive modiﬁcation on
Lys
99—sumoylation and ubiquitination—might have
opposite effects on the enzyme isopeptidase activity.
Importantly, USP25 is able to auto-deubiquitinate itself
possibly representing a mechanism of auto-regulation [78].
ATM/IR-Dependent Phosphorylation of USP28
A deubiquitinase USP28 binds to the SCF
Fbw7 ubiquitin E3
ligase, stabilizing Myc, and therefore promoting cell
proliferation [82]. Moreover, USP28 binds checkpoint
proteins 53BP1, Claspin, and Mdc1 [83]. In response to IR,
USP28 becomes phosphorylated on Ser
67 and Ser
714 in an
ATM-dependent manner [83]. This modiﬁcation is likely to
regulate the complex-formation with the DNA checkpoint
proteins, supported by the fact that cell exposure to irra-
diation induces Myc dissociation from USP28 [82].
Phosphorylation of USP44 during Mitosis
USP44, a predominantly nuclear DUB and an important
regulator of the spindle checkpoint, undergoes phosphor-
ylation during mitosis [84]. This step may activate USP44
speciﬁcally for the checkpoint arrest, regulated for instance
by mitotic cyclin-dependent kinases or spindle checkpoint
kinases [85]. Moreover, USP44 is a documented target for
Lys
48- and Lys
63-linked polyubiquitination, but the effect
of these modiﬁcations is not yet understood [84].
PTMs on DUBs Identiﬁed by Global Proteomics Studies
In addition to the biochemically-characterized examples of
PTMs, several high-throughput studies aimed at mapping
the phosphoproteome, ubiquitinome, and acetylome yiel-
ded information on additional post-translationally modiﬁed
residues in DUBs (several such studies are summarized in
Table 2,[ 65, 86–114]). Strikingly, large-scale phospho-
proteomics studies have found 37 out of 55 USPs to be
phosphorylated in vivo (reviewed in [115]). Global phos-
phoproteome analyses targeted to a particular kinase might
be of special value, placing a phosphorylated DUB within a
biological context. For instance, Matsuoka et al. [90]
detected various DUBs as kinase substrates of ATM (ataxia
telangiectasia mutated) and ATR (ATM and Rad3-related)
in response to the DNA damage, which include USP1,
UCHL3, USP19, USP24, USP28, and USP34, although the
relevance of ATM/ATR-mediated phosphorylation of these
enzymes is presently unclear [90]. Furthermore, proteomic
studies such as [8] provide information on novel protein–
protein interactions, including association with kinases,
methyl transferases, and other proteins that might post-
translationally modify DUBs.
All this indicates that the number of the PTMs affecting
DUBs must be extensive, providing a great scope for future
studies exploring roles of these already discovered modiﬁ-
cations. Location of the modiﬁable residues within various
DUB domains might give an initial clue on the mechanistic
effect of PTMs on DUB function. For instance, different
outcomes are to be expected for modiﬁcations occurring
within the ubiquitin-binding domain, components of the
catalytic site, or protein–protein interaction domains.
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123Multi-PTM Crosstalk
Although there are multiple examples of post-translation-
ally modiﬁed DUBs, the biochemical data is too scarce to
draw any general conclusions, especially in relation to
PTM-mediated regulation of the catalytic activity of DUBs.
Future studies are likely to reveal trans-regulatory mecha-
nisms of PTMs in the control of DUB catalytic activity
and function. Such complex crosstalks between pathways
have been recognized for many proteins, perhaps best
described for kinases and histones. For instance, in some
cases priming phosphorylation events are necessary to
enable subsequent phosphorylation, sumoylation, or ubiq-
uitination, while methylation or ubiquitination of certain
residues in histones might be a prerequisite for their acet-
ylation (reviewed in [116]). So far, no example of a similar
mechanism has been discovered for DUBs, but they are
anticipated. In particular, an occurrence of a phosphodeg-
ron, or a priming phosphorylation event necessary for
recognition by an E3 ubiquitin ligase, leading to ubiquiti-
nation and proteasomal degradation, should be carefully
examined for DUBs down-regulated by phosphorylation
events. For instance, phosphorylation of USP25 [80] might
trigger subsequent Lys
48-polyubiquitination resulting in
proteasomal degradation. On the other hand, phosphory-
lation-driven negative regulation of ubiquitination might
also be common. For example, it would be interesting to
investigate this mechanism for USP8, since phosphoryla-
tion of Thr
907 leads to accumulation of this protein [74, 75].
Another attractive aspect of post-translational events is a
direct competition for a modiﬁable residue, such as for
USP25, where Lys
99 has been shown to be both ubiquiti-
nated and sumoylated, with a potentially opposite func-
tional outcome [78, 81].
Auto-Regulatory Mechanisms Keep DUBs in Check
Internal adaptive mechanisms controlling kinase enzymatic
activity and therefore cell homeostasis have been known
for a long time (reviewed in [117, 118]), but they have also
been described for E3 ubiquitin ligases (e.g., Smurf2 [119])
and acetyltransferases (e.g., Rtt109 [120]). Since attach-
ment of ubiquitin or ubiquitin-like molecules to protein
substrates has been recognized as a multi-purpose regula-
tory modiﬁcation, self-deubiquitination represents an
attractive means of auto-regulation, whether it concerns
control over lifespan, localization, or catalytic activity of
DUBs. Indeed, this principle has been proposed for UCH-
L1 [57], USP6 [59], and USP25 [78]. Monoubiquitination
is particularly interesting since it impairs deubiquitinating
properties of UCH-L1, while USP25 catalytic activity is
most likely induced by this PTM [57, 78]. These studies
indicate that auto-deubiquitination might contribute to
both, inhibition and activation of the DUB function.
Further knowledge on how DUB function is regulated
by PTMs may provide novel insights into their biology.
Moreover, since many DUBs are implicated in cancer,
inﬂammation, microbial disease, and neurodegeneration,
novel insights into PTM-mediated regulation of DUBs
might provide opportunities for combining inhibitors of
DUBs and enzymes responsible for regulatory PTMs (e.g.,
kinase or phosphatase inhibitors) as more efﬁcient entry
points for pharmacological intervention strategies.
Acknowledgements B.M.K. is supported by the NIHR Biomedical
Research Centre, Oxford, UK, and an Action Medical Research Grant
(Charity No. 208701 and SC039284). M.J.E. is supported by the
USDA NIFA grant 2009-34609-20222. Approved for publication as
Journal Article No. J-12003 of the Mississippi Agricultural and
Forestry Experiment Station, Mississippi State University.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Nijman, S. M., Luna-Vargas, M. P., Velds, A., Brummelkamp,
T. R., Dirac, A. M., Sixma, T. K., et al. (2005). A genomic and
functional inventory of deubiquitinating enzymes. Cell, 123,
773–786.
2. Wing, S. S. (2003). Deubiquitinating enzymes–the importance
of driving in reverse along the ubiquitin-proteasome pathway.
International Journal of Biochemistry and Cell Biology, 35,
590–605.
3. Piotrowski, J., Beal, R., Hoffman, L., Wilkinson, K. D., Cohen,
R. E., & Pickart, C. M. (1997). Inhibition of the 26 S proteasome
by polyubiquitin chains synthesized to have deﬁned lengths.
Journal of Biological Chemistry, 272, 23712–23721.
4. Raasi, S., Varadan, R., Fushman, D., & Pickart, C. M. (2005).
Diverse polyubiquitin interaction properties of ubiquitin-asso-
ciated domains. Nature Structural and Molecular Biology, 12,
708–714.
5. Wilkinson, K. D., Tashayev, V. L., O’Connor, L. B., Larsen, C.
N., Kasperek, E., & Pickart, C. M. (1995). Metabolism of the
polyubiquitin degradation signal: Structure, mechanism, and
role of isopeptidase T. Biochemistry, 34, 14535–14546.
6. D’Andrea, A., & Pellman, D. (1998). Deubiquitinating enzymes:
A new class of biological regulators. Critical Reviews in Bio-
chemistry and Molecular Biology, 33, 337–352.
7. Komander, D., Clague, M. J., & Urbe, S. (2009). Breaking the
chains: Structure and function of the deubiquitinases. Nature
Reviews Molecular Cell Biology, 10, 550–563.
8. Sowa, M. E., Bennett, E. J., Gygi, S. P., & Harper, J. W. (2009).
Deﬁning the human deubiquitinating enzyme interaction land-
scape. Cell, 138, 389–403.
9. Singhal, S., Taylor, M. C., & Baker, R. T. (2008). Deubiquity-
lating enzymes and disease. Biomedical Central Biochemistry,
9(Suppl 1), S3.
10. Reyes-Turcu, F. E., Ventii, K. H., & Wilkinson, K. D. (2009).
Regulation and cellular roles of ubiquitin-speciﬁc deubiquiti-
nating enzymes. Annual Review of Biochemistry, 78, 363–397.
34 Cell Biochem Biophys (2011) 60:21–38
12311. Dang, L. C., Melandri, F. D., & Stein, R. L. (1998). Kinetic and
mechanistic studies on the hydrolysis of ubiquitin C-terminal
7-amido-4-methylcoumarin by deubiquitinating enzymes. Bio-
chemistry, 37, 1868–1879.
12. Edelmann, M. J., Iphofer, A., Akutsu, M., Altun, M., di Gleria,
K., Kramer, H. B., et al. (2009). Structural basis and speciﬁcity
of human otubain 1-mediated deubiquitination. Biochemical
Journal, 418, 379–390.
13. Hu, M., Li, P., Li, M., Li, W., Yao, T., Wu, J. W., et al. (2002).
Crystal structure of a UBP-family deubiquitinating enzyme in
isolation and in complex with ubiquitin aldehyde. Cell, 111,
1041–1054.
14. Hu, M., Li, P., Song, L., Jeffrey, P. D., Chenova, T. A., Wil-
kinson, K. D., et al. (2005). Structure and mechanisms of the
proteasome-associated deubiquitinating enzyme USP14. EMBO
Journal, 24, 3747–3756.
15. Johnston, S. C., Larsen, C. N., Cook, W. J., Wilkinson, K. D., &
Hill, C. P. (1997). Crystal structure of a deubiquitinating
enzyme (human UCH-L3) at 1.8 A resolution. EMBO Journal,
16, 3787–3796.
16. Johnston, S. C., Riddle, S. M., Cohen, R. E., & Hill, C. P.
(1999). Structural basis for the speciﬁcity of ubiquitin C-ter-
minal hydrolases. EMBO Journal, 18, 3877–3887.
17. Lin, S. C., Chung, J. Y., Lamothe, B., Rajashankar, K., Lu, M.,
Lo, Y. C., et al. (2008). Molecular basis for the unique
deubiquitinating activity of the NF-kappaB inhibitor A20.
Journal of Molecular Biology, 376, 526–540.
18. Misaghi, S., Galardy, P. J., Meester, W. J., Ovaa, H., Ploegh, H.
L., & Gaudet, R. (2005). Structure of the ubiquitin hydrolase
UCH-L3 complexed with a suicide substrate. Journal of Bio-
logical Chemistry, 280, 1512–1520.
19. Reyes-Turcu, F. E., Horton, J. R., Mullally, J. E., Heroux, A.,
Cheng, X., & Wilkinson, K. D. (2006). The ubiquitin binding
domain ZnF UBP recognizes the C-terminal diglycine motif of
unanchored ubiquitin. Cell, 124, 1197–1208.
20. Ventii, K. H., & Wilkinson, K. D. (2008). Protein partners of
deubiquitinating enzymes. Biochemical Journal, 414, 161–175.
21. Borodovsky, A., Kessler, B. M., Casagrande, R., Overkleeft, H.
S., Wilkinson, K. D., & Ploegh, H. L. (2001). A novel active
site-directed probe speciﬁc for deubiquitylating enzymes reveals
proteasome association of USP14. EMBO Journal, 20,
5187–5196.
22. Verma, R., Aravind, L., Oania, R., McDonald, W. H., Yates, J.
R., 3rd, Koonin, E. V., et al. (2002). Role of Rpn11 metallo-
protease in deubiquitination and degradation by the 26S pro-
teasome. Science, 298, 611–615.
23. McCullough, J., Row, P. E., Lorenzo, O., Doherty, M., Beynon,
R., Clague, M. J., et al. (2006). Activation of the endosome-
associated ubiquitin isopeptidase AMSH by STAM, a compo-
nent of the multivesicular body-sorting machinery. Current
Biology, 16, 160–165.
24. Yao, T., Song, L., Jin, J., Cai, Y., Takahashi, H., Swanson, S. K.,
et al. (2008). Distinct modes of regulation of the Uch37 de-
ubiquitinating enzyme in the proteasome and in the Ino80
chromatin-remodeling complex. Molecular Cell, 31, 909–917.
25. Huang, T. T., Nijman, S. M., Mirchandani, K. D., Galardy, P. J.,
Cohn, M. A., Haas, W., et al. (2006). Regulation of mono-
ubiquitinated PCNA by DUB autocleavage. Nature Cell Biol-
ogy, 8, 339–347.
26. Kovalenko, A., Chable-Bessia, C., Cantarella, G., Israel, A.,
Wallach, D., & Courtois, G. (2003). The tumour suppressor
CYLD negatively regulates NF-kappaB signalling by deubiq-
uitination. Nature, 424, 801–805.
27. Brummelkamp,T.R.,Nijman,S.M.,Dirac,A.M.,&Bernards,R.
(2003). Loss of the cylindromatosis tumour suppressor inhibits
apoptosis by activating NF-kappaB. Nature, 424, 797–801.
28. Trompouki, E., Hatzivassiliou, E., Tsichritzis, T., Farmer, H.,
Ashworth, A., & Mosialos, G. (2003). CYLD is a deubiquiti-
nating enzyme that negatively regulates NF-kappaB activation
by TNFR family members. Nature, 424, 793–796.
29. Sun, S. C. (2010). CYLD: A tumor suppressor deubiquitinase
regulating NF-kappaB activation and diverse biological pro-
cesses. Cell Death and Differentiation, 17, 25–34.
30. Lim,J.H.,Jono,H.,Koga,T.,Woo,C.H.,Ishinaga,H.,Bourne,P.,
et al. (2007). Tumor suppressor CYLD acts as a negative regulator
for non-typeable Haemophilus inﬂuenza-induced inﬂammation in
the middle ear and lung of mice. PLoS One, 2,e 1 0 3 2 .
31. Lim, J. H., Stirling, B., Derry, J., Koga, T., Jono, H., Woo, C. H.,
et al. (2007). Tumor suppressor CYLD regulates acute lung
injury in lethal Streptococcus pneumoniae infections. Immunity,
27, 349–360.
32. Sakai, A., Koga, T., Lim, J. H., Jono, H., Harada, K.,
Szymanski, E., et al. (2007). The bacterium, nontypeable
Haemophilus inﬂuenzae, enhances host antiviral response by
inducing Toll-like receptor 7 expression: Evidence for negative
regulation of host anti-viral response by CYLD. FEBS Journal,
274, 3655–3668.
33. Lim, J. H., Ha, U. H., Woo, C. H., Xu, H., & Li, J. D. (2008).
CYLD is a crucial negative regulator of innate immune response
in Escherichia coli pneumonia. Cellular Microbiology, 10,
2247–2256.
34. Reiley, W., Zhang, M., Wu, X., Granger, E., & Sun, S. C.
(2005). Regulation of the deubiquitinating enzyme CYLD by
IkappaB kinase gamma-dependent phosphorylation. Molecular
and Cellular Biology, 25, 3886–3895.
35. Hutti, J. E., Shen, R. R., Abbott, D. W., Zhou, A. Y., Sprott, K.
M., Asara, J. M., et al. (2009). Phosphorylation of the tumor
suppressor CYLD by the breast cancer oncogene IKKepsilon
promotes cell transformation. Molecular Cell, 34, 461–472.
36. Lee, E. G., Boone, D. L., Chai, S., Libby, S. L., Chien, M.,
Lodolce, J. P., et al. (2000). Failure to regulate TNF-induced
NF-kappaB and cell death responses in A20-deﬁcient mice.
Science, 289, 2350–2354.
37. Wertz, I. E., O’Rourke, K. M., Zhou, H., Eby, M., Aravind, L.,
Seshagiri, S., et al. (2004). De-ubiquitination and ubiquitin
ligase domains of A20 downregulate NF-kappaB signalling.
Nature, 430, 694–699.
38. Boone, D. L., Turer, E. E., Lee, E. G., Ahmad, R. C., Wheeler,
M. T., Tsui, C., et al. (2004). The ubiquitin-modifying enzyme
A20 is required for termination of Toll-like receptor responses.
Nature Immunology, 5, 1052–1060.
39. Balakirev, M. Y., & Wilkinson, K. D. (2008). OTU takes the
chains OUT. Nature Chemical Biology, 4, 227–228.
40. Heyninck, K., & Beyaert, R. (2005). A20 inhibits NF-kappaB
activation by dual ubiquitin-editing functions. Trends in Bio-
chemical Sciences, 30, 1–4.
41. Hutti, J. E., Turk, B. E., Asara, J. M., Ma, A., Cantley, L. C., &
Abbott, D. W. (2007). IkappaB kinase beta phosphorylates the
K63 deubiquitinase A20 to cause feedback inhibition of the NF-
kappaB pathway. Molecular and Cellular Biology, 27,
7451–7461.
42. Nicastro, G., Masino, L., Esposito, V., Menon, R. P., De
Simone, A., Fraternali, F., et al. (2009). Josephin domain of
ataxin-3 contains two distinct ubiquitin-binding sites. Biopoly-
mers, 91, 1203–1214.
43. Winborn, B. J., Travis, S. M., Todi, S. V., Scaglione, K. M., Xu,
P., Williams, A. J., et al. (2008). The deubiquitinating enzyme
ataxin-3, a polyglutamine disease protein, edits Lys63 linkages
in mixed linkage ubiquitin chains. Journal of Biological
Chemistry, 283, 26436–26443.
44. Todi, S. V., Laco, M. N., Winborn, B. J., Travis, S. M., Wen, H.
M., & Paulson, H. L. (2007). Cellular turnover of the
Cell Biochem Biophys (2011) 60:21–38 35
123polyglutamine disease protein ataxin-3 is regulated by its catalytic
activity. Journal of Biological Chemistry, 282, 29348–29358.
45. Todi, S. V., Winborn, B. J., Scaglione, K. M., Blount, J. R.,
Travis, S. M., & Paulson, H. L. (2009). Ubiquitination directly
enhances activity of the deubiquitinating enzyme ataxin-3.
EMBO Journal, 28, 372–382.
46. Mueller, T., Breuer, P., Schmitt, I., Walter, J., Evert, B. O., &
Wullner, U. (2009). CK2-dependent phosphorylation determines
cellular localization and stability of ataxin-3. Human Molecular
Genetics, 18, 3334–3343.
47. Wang, T., Yin, L., Cooper, E. M., Lai, M. Y., Dickey, S.,
Pickart, C. M., et al. (2009). Evidence for bidentate substrate
binding as the basis for the K48 linkage speciﬁcity of otubain 1.
Journal of Molecular Biology, 386, 1011–1023.
48. Soares, L., Seroogy, C., Skrenta, H., Anandasabapathy, N.,
Lovelace, P., Chung, C. D., et al. (2004). Two isoforms of
otubain 1 regulate T cell anergy via GRAIL. Nature Immunol-
ogy, 5, 45–54.
49. Lin, J. T., Lineberry, N. B., Kattah, M. G., Su, L. L., Utz, P. J.,
Fathman, C. G., et al. (2009). Naive CD4 t cell proliferation is
controlled by mammalian target of rapamycin regulation of
GRAIL expression. Journal of Immunology, 182, 5919–5928.
50. Edelmann, M. J., Kramer, H. B., Altun, M., & Kessler, B. M.
(2010). Post-translational modiﬁcation of the deubiquitinating
enzyme otubain 1 modulates active RhoA levels and suscepti-
bility to Yersinia invasion. FEBS Journal, 277, 2515–2530.
51. Nakada, S., Tai, I., Panier, S., Al-Hakim, A., Iemura, S., Juang,
Y. C., et al. (2010). Non-canonical inhibition of DNA damage-
dependent ubiquitination by OTUB1. Nature, 466, 941–946.
52. Rose, A., & Schlieker, C. (2010). DNA repair: Blocking ubiq-
uitin transfer. Nature, 466, 929–930.
53. Cai, S. Y., Babbitt, R. W., & Marchesi, V. T. (1999). A mutant
deubiquitinating enzyme (Ubp-M) associates with mitotic
chromosomes and blocks cell division. Proceedings of the
National Academy of Sciences USA, 96, 2828–2833.
54. Joo, H. Y., Zhai, L., Yang, C., Nie, S., Erdjument-Bromage, H.,
Tempst, P., et al. (2007). Regulation of cell cycle progression
and gene expression by H2A deubiquitination. Nature, 449,
1068–1072.
55. Day, I. N., & Thompson, R. J. (2010). UCHL1 (PGP 9.5):
Neuronal biomarker and ubiquitin system protein. Progress in
Neurobiology, 90, 327–362.
56. Cole, R. N., & Hart, G. W. (2001). Cytosolic O-glycosylation is
abundant in nerve terminals. Journal of Neurochemistry, 79,
1080–1089.
57. Meray, R. K., & Lansbury, P. T., Jr. (2007). Reversible mono-
ubiquitination regulates the Parkinson disease-associated ubiq-
uitin hydrolase UCH-L1. Journal of Biological Chemistry, 282,
10567–10575.
58. Oliveira, A. M., Hsi, B. L., Weremowicz, S., Rosenberg, A. E.,
Dal Cin, P., Joseph, N., et al. (2004). USP6 (Tre2) fusion
oncogenes in aneurysmal bone cyst. Cancer Research, 64,
1920–1923.
59. Shen, C., Ye, Y., Robertson, S. E., Lau, A. W., Mak, D. O., &
Chou, M. M. (2005). Calcium/calmodulin regulates ubiquitina-
tion of the ubiquitin-speciﬁc protease TRE17/USP6. Journal of
Biological Chemistry, 280, 35967–35973.
60. Kessler, B. M., Fortunati, E., Melis, M., Pals, C. E., Clevers, H.,
& Maurice, M. M. (2007). Proteome changes induced by knock-
down of the deubiquitylating enzyme HAUSP/USP7. Journal of
Proteome Research, 6, 4163–4172.
61. Brooks, C. L., & Gu, W. (2004). Dynamics in the p53-Mdm2
ubiquitination pathway. Cell Cycle, 3, 895–899.
62. Lee, J. T., & Gu, W. (2010). The multiple levels of regulation by
p53 ubiquitination. Cell Death Differentiation, 17, 86–92.
63. Li, M., Chen, D., Shiloh, A., Luo, J., Nikolaev, A. Y., Qin, J.,
et al. (2002). Deubiquitination of p53 by HAUSP is an important
pathway for p53 stabilization. Nature, 416, 648–653.
64. Meulmeester, E., Maurice, M. M., Boutell, C., Teunisse, A. F.,
Ovaa, H., Abraham, T. E., et al. (2005). Loss of HAUSP-med-
iated deubiquitination contributes to DNA damage-induced
destabilization of Hdmx and Hdm2. Molecular Cell, 18,
565–576.
65. Beausoleil, S. A., Jedrychowski, M., Schwartz, D., Elias, J. E.,
Villen, J., Li, J., et al. (2004). Large-scale characterization of
HeLa cell nuclear phosphoproteins. Proceedings of the National
Academy of Sciences USA, 101, 12130–12135.
66. Fernandez-Montalvan, A., Bouwmeester, T., Joberty, G., Mader,
R., Mahnke, M., Pierrat, B., et al. (2007). Biochemical charac-
terization of USP7 reveals post-translational modiﬁcation sites
and structural requirements for substrate processing and sub-
cellular localization. FEBS Journal, 274, 4256–4270.
67. Holowaty, M. N., Sheng, Y., Nguyen, T., Arrowsmith, C., &
Frappier, L. (2003). Protein interaction domains of the ubiquitin-
speciﬁc protease, USP7/HAUSP. Journal of Biological Chem-
istry, 278, 47753–47761.
68. Boutell, C., Canning, M., Orr, A., & Everett, R. D. (2005).
Reciprocal activities between herpes simplex virus type 1 reg-
ulatory protein ICP0, a ubiquitin E3 ligase, and ubiquitin-spe-
ciﬁc protease USP7. Journal of Virology, 79, 12342–12354.
69. Mizuno, E., Kobayashi, K., Yamamoto, A., Kitamura, N., &
Komada, M. (2006). A deubiquitinating enzyme UBPY regu-
lates the level of protein ubiquitination on endosomes. Trafﬁc, 7,
1017–1031.
70. Ballif, B. A., Cao, Z., Schwartz, D., Carraway, K. L., 3rd, &
Gygi, S. P. (2006). Identiﬁcation of 14–3-3 epsilon substrates
from embryonic murine brain. Journal of Proteome Research, 5,
2372–2379.
71. Ballif, B. A., Villen, J., Beausoleil, S. A., Schwartz, D., & Gygi,
S. P. (2004). Phosphoproteomic analysis of the developing
mouse brain. Molecular and Cellular Proteomics, 3, 1093–1101.
72. Mizuno, E., Kitamura, N., & Komada, M. (2007). 14–3-3-
dependent inhibition of the deubiquitinating activity of UBPY
and its cancellation in the M phase. Experimental Cell Research,
313, 3624–3634.
73. Alwan, H. A. J., & van Leeuwen, J. E. M. (2007). UBPY-
mediated epidermal growth factor receptor (EGFR) de-ubiqui-
tination promotes EGFR degradation. Journal of Biological
Chemistry, 282, 1658–1669.
74. Cao, Z. W., Wu, X. L., Yen, L., Sweeney, C., & Carraway, K. L.
(2007). Neuregulin-induced ErbB3 downregulation is mediated
by a protein stability cascade involving the E3 ubiquitin ligase
Nrdp1. Molecular and Cellular Biology, 27, 2180–2188.
75. Cai, J. J., Crotty, T. M., Reichert, E., Carraway, K. L., Stafforini,
D. M., & Topham, M. K. (2010). Diacylglycerol Kinase delta
and Protein Kinase C alpha Modulate Epidermal Growth Factor
Receptor Abundance and Degradation through Ubiquitin-
speciﬁc Protease 8. Journal of Biological Chemistry, 285,
6952–6959.
76. Yuan, J., Luo, K., Zhang, L., Cheville, J. C., & Lou, Z. (2010).
USP10 regulates p53 localization and stability by deubiquiti-
nating p53. Cell, 140, 384–396.
77. Valero, R., Marfany, G., Gonzalez-Angulo, O., Gonzalez-
Gonzalez, G., Puelles, L., & Gonzalez-Duarte, R. (1999). USP25,
a novel gene encoding a deubiquitinating enzyme, is located in
the gene-poor region 21q11.2. Genomics, 62, 395–405.
78. Denuc, A., Bosch-Comas, A., Gonzalez-Duarte, R., & Marfany,
G. (2009). The UBA-UIM domains of the USP25 regulate the
enzyme ubiquitination state and modulate substrate recognition.
PLoS One, 4, e5571.
36 Cell Biochem Biophys (2011) 60:21–38
12379. Bosch-Comas, A., Lindsten, K., Gonzalez-Duarte, R., Masucci,
M. G., & Marfany, G. (2006). The ubiquitin-speciﬁc protease
USP25 interacts with three sarcomeric proteins. Cellular and
Molecular Life Sciences, 63, 723–734.
80. Cholay, M., Reverdy, C., Benarous, R., Colland, F., & Daviet, L.
(2010). Functional interaction between the ubiquitin-speciﬁc
protease 25 and the SYK tyrosine kinase. Experimental Cell
Research, 316, 667–675.
81. Meulmeester, E., Kunze, M., Hsiao, H. H., Urlaub, H., & Mel-
chior, F. (2008). Mechanism and consequences for paralog-
speciﬁc sumoylation of ubiquitin-speciﬁc protease 25. Molecu-
lar Cell, 30, 610–619.
82. Popov, N., Herold, S., Llamazares, M., Schulein, C., & Eilers,
M. (2007). Fbw7 and Usp28 regulate myc protein stability in
response to DNA damage. Cell Cycle, 6, 2327–2331.
83. Zhang, D., Zaugg, K., Mak, T. W., & Elledge, S. J. (2006). A
role for the deubiquitinating enzyme USP28 in control of the
DNA-damage response. Cell, 126, 529–542.
84. Suresh, B., Ramakrishna, S., Lee, H. J., Choi, J. H., Kim, J. Y.,
Ahn, W. S., et al. (2010). K48- and K63-linked polyubiquiti-
nation of deubiquitinating enzyme USP44. Cell Biology Inter-
national, 34, 799–808.
85. Stegmeier, F., Rape, M., Draviam, V. M., Nalepa, G., Sowa, M.
E., Ang, X. L. L., et al. (2007). Anaphase initiation is regulated
by antagonistic ubiquitination and deubiquitination activities.
Nature, 446, 876–881.
86. Gauci, S., Helbig, A. O., Slijper, M., Krijgsveld, J., Heck, A. J.,
& Mohammed, S. (2009). Lys-N and trypsin cover comple-
mentary parts of the phosphoproteome in a reﬁned SCX-based
approach. Analytical Chemistry, 81, 4493–4501.
87. Cantin, G. T., Yi, W., Lu, B., Park, S. K., Xu, T., Lee, J. D.,
et al. (2008). Combining protein-based IMAC, peptide-based
IMAC, and MudPIT for efﬁcient phosphoproteomic analysis.
Journal of Proteome Research, 7, 1346–1351.
88. Olsen, J. V., Blagoev, B., Gnad, F., Macek, B., Kumar, C.,
Mortensen, P., et al. (2006). Global, in vivo, and site-speciﬁc
phosphorylation dynamics in signaling networks. Cell, 127,
635–648.
89. Beausoleil, S. A., Villen, J., Gerber, S. A., Rush, J., & Gygi, S.
P. (2006). A probability-based approach for high-throughput
protein phosphorylation analysis and site localization. Nature
Biotechnology, 24, 1285–1292.
90. Matsuoka, S., Ballif, B. A., Smogorzewska, A., McDonald, E.
R., 3rd, Hurov, K. E., Luo, J., et al. (2007). ATM and ATR
substrate analysis reveals extensive protein networks responsive
to DNA damage. Science, 316, 1160–1166.
91. Heibeck, T. H., Ding, S. J., Opresko, L. K., Zhao, R.,
Schepmoes, A. A., Yang, F., et al. (2009). An extensive survey
of tyrosine phosphorylation revealing new sites in human
mammary epithelial cells. Journal of Proteome Research, 8,
3852–3861.
92. Dephoure, N., Zhou, C., Villen, J., Beausoleil, S. A., Bakalarski,
C. E., Elledge, S. J., et al. (2008). A quantitative atlas of mitotic
phosphorylation. Proceedings of the National Academy of
Sciences USA, 105, 10762–10767.
93. Mayya, V., Lundgren, D. H., Hwang, S. I., Rezaul, K., Wu, L.,
Eng, J. K., et al. (2009). Quantitative phosphoproteomic analysis
of T cell receptor signaling reveals system-wide modulation of
protein-protein interactions. Science Signaling, 2, ra46.
94. Rush, J., Moritz, A., Lee, K. A., Guo, A., Goss, V. L., Spek, E.
J., et al. (2005). Immunoafﬁnity proﬁling of tyrosine phos-
phorylation in cancer cells. Nature Biotechnology, 23, 94–101.
95. Wolf-Yadlin, A., Hautaniemi, S., Lauffenburger, D. A., &
White, F. M. (2007). Multiple reaction monitoring for robust
quantitative proteomic analysis of cellular signaling networks.
Proceedings of the National Academy of Sciences USA, 104,
5860–5865.
96. Yu, L. R., Zhu, Z., Chan, K. C., Issaq, H. J., Dimitrov, D. S., &
Veenstra, T. D. (2007). Improved titanium dioxide enrichment
of phosphopeptides from HeLa cells and high conﬁdent phos-
phopeptide identiﬁcation by cross-validation of MS/MS and
MS/MS/MS spectra. Journal of Proteome Research, 6,
4150–4162.
97. Daub, H., Olsen, J. V., Bairlein, M., Gnad, F., Oppermann, F. S.,
Korner, R., et al. (2008). Kinase-selective enrichment enables
quantitative phosphoproteomics of the kinome across the cell
cycle. Molecular Cell, 31, 438–448.
98. Molina, H., Horn, D. M., Tang, N., Mathivanan, S., & Pandey,
A. (2007). Global proteomic proﬁling of phosphopeptides using
electron transfer dissociation tandem mass spectrometry. Pro-
ceedings of the National Academy of Sciences USA, 104,
2199–2204.
99. Giorgianni, F., Zhao, Y., Desiderio, D. M., & Beranova-Gior-
gianni, S. (2007). Toward a global characterization of the
phosphoproteome in prostate cancer cells: Identiﬁcation of
phosphoproteins in the LNCaP cell line. Electrophoresis, 28,
2027–2034.
100. Tang, L. Y., Deng, N., Wang, L. S., Dai, J., Wang, Z. L., Jiang,
X. S., et al. (2007). Quantitative phosphoproteome proﬁling of
Wnt3a-mediated signaling network: Indicating the involvement
of ribonucleoside-diphosphate reductase M2 subunit phosphor-
ylation at residue serine 20 in canonical Wnt signal transduction.
Molecular Cell Proteomics, 6, 1952–1967.
101. Han, G., Ye, M., Zhou, H., Jiang, X., Feng, S., Tian, R., et al.
(2008). Large-scale phosphoproteome analysis of human liver
tissue by enrichment and fractionation of phosphopeptides
with strong anion exchange chromatography. Proteomics, 8,
1346–1361.
102. Oppermann, F. S., Gnad, F., Olsen, J. V., Hornberger, R., Greff,
Z., Keri, G., et al. (2009). Large-scale proteomics analysis of the
human kinome. Molecular Cell Proteomics, 8, 1751–1764.
103. Carrascal, M., Ovelleiro, D., Casas, V., Gay, M., & Abian, J.
(2008). Phosphorylation analysis of primary human T lympho-
cytes using sequential IMAC and titanium oxide enrichment.
Journal of Proteome Research, 7, 5167–5176.
104. Imami, K., Sugiyama, N., Kyono, Y., Tomita, M., & Ishihama,
Y. (2008). Automated phosphoproteome analysis for cultured
cancer cells by two-dimensional nanoLC-MS using a calcined
titania/C18 biphasic column. Analytical Science, 24, 161–166.
105. Brill, L. M., Salomon, A. R., Ficarro, S. B., Mukherji, M.,
Stettler-Gill, M., & Peters, E. C. (2004). Robust phospho-
proteomic proﬁling of tyrosine phosphorylation sites from
human T cells using immobilized metal afﬁnity chromatog-
raphy and tandem mass spectrometry. Analytical Chemistry,
76, 2763–2772.
106. Wang,B.,Malik,R.,Nigg,E.A.,&Korner,R.(2008).Evaluation
of the low-speciﬁcity protease elastase for large-scale phospho-
proteome analysis. Analytical Chemistry, 80, 9526–9533.
107. Zahedi, R. P., Lewandrowski, U., Wiesner, J., Wortelkamp, S.,
Moebius, J., Schutz, C., et al. (2008). Phosphoproteome of
resting human platelets. Journal of Proteome Research, 7,
526–534.
108. Nousiainen, M., Sillje, H. H., Sauer, G., Nigg, E. A., & Korner,
R. (2006). Phosphoproteome analysis of the human mitotic
spindle. Proceedings of the National Academy of Sciences USA,
103, 5391–5396.
109. Wang, X., Chen, C. F., Baker, P. R., Chen, P. L., Kaiser, P., &
Huang, L. (2007). Mass spectrometric characterization of the
afﬁnity-puriﬁed human 26S proteasome complex. Biochemistry,
46, 3553–3565.
Cell Biochem Biophys (2011) 60:21–38 37
123110. Denis, N. J., Vasilescu, J., Lambert, J. P., Smith, J. C., & Figeys,
D. (2007). Tryptic digestion of ubiquitin standards reveals an
improved strategy for identifying ubiquitinated proteins by mass
spectrometry. Proteomics, 7, 868–874.
111. Mu, J. J., Wang, Y., Luo, H., Leng, M., Zhang, J., Yang, T., et al.
(2007). A proteomic analysis of ataxia telangiectasia-mutated
(ATM)/ATM-Rad3-related (ATR) substrates identiﬁes the ubiq-
uitin-proteasome system as a regulator for DNA damage check-
points. Journal of Biological Chemistry, 282, 17330–17334.
112. Sui, S. H., Wang, J. L., Yang, B., Song, L., Zhang, J. Y., Chen,
M., et al. (2008). Phosphoproteome analysis of the human
Chang liver cells using SCX and a complementary mass spec-
trometric strategy. Proteomics, 8, 2024–2034.
113. Dephoure, N., Zhou, C., Villen, J., Beausoleil, S. A., Bakalarski,
C. E., Elledge, S. J., et al. (2008). A quantitative atlas of mitotic
phosphorylation. Proceedings of the National Academy of Sci-
ences of the United States of America, 105, 10762–10767.
114. Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman,
M., Walther, T. C., et al. (2009). Lysine acetylation targets
protein complexes and co-regulates major cellular functions.
Science, 325, 834–840.
115. Lopez-Otin, C., & Hunter, T. (2010). The regulatory crosstalk
between kinases and proteases in cancer. Nature Reviews Can-
cer, 10, 278–292.
116. Hunter, T. (2007). The age of crosstalk: Phosphorylation,
ubiquitination, and beyond. Molecular Cell, 28, 730–738.
117. Soderling, T. R. (1990). Protein kinases. Regulation by autoinhib-
itory domains. Journal of Biological Chemistry, 265, 1823–1826.
118. Pufall, M. A., & Graves, B. J. (2002). Autoinhibitory domains:
Modular effectors of cellular regulation. Annual Review of Cell
and Developmental Biology, 18, 421–462.
119. Wiesner, S., Ogunjimi, A. A., Wang, H. R., Rotin, D., Sicheri,
F., Wrana, J. L., et al. (2007). Autoinhibition of the HECT-
Type ubiquitin ligase smurf2 through its c2 domain. Cell, 130,
651–662.
120. Stavropoulos, P., Nagy, V., Blobel, G., & Hoelz, A. (2008).
Molecular basis for the autoregulation of the protein acetyl
transferase Rtt109. Proceedings of the National Academy of
Sciences USA, 105, 12236–12241.
121. Wada, K., & Kamitani, T. (2006). UnpEL/Usp4 is ubiquitinated
by Ro52 and deubiquitinated by itself. Biochemical and Bio-
physical Research Communications, 342, 253–258.
38 Cell Biochem Biophys (2011) 60:21–38
123